英夫利西单抗治疗难治性重症类风湿关节炎临床研究  

Clinical research of infliximab in patients with severe refractory rheumatoid arthritis

作　　者：谢希[1] 陈进伟[1] 高洁生[1] 李芬[1] 田静[1] 杜金烽[1] 王静[1] 毛妮[1] 

机构地区：[1]中南大学湘雅二医院风湿免疫科,长沙410011

出　　处：《中国新药杂志》2010年第4期304-307,共4页Chinese Journal of New Drugs

摘　　要：目的:观察英夫利西单抗(infliximab)治疗难治性重症类风湿关节炎(RA)8周的临床疗效及不良反应。方法:10例难治性重症RA患者接受英夫利西单抗治疗(0周,第2周,第6周),观察治疗前、第1周、第4周及第8周各项观察指标变化,并记录不良反应发生情况。结果:10例RA患者临床指标、实验室指标及DAS28评分均有显著改善(P<0.05),未见明显不良反应。结论:英夫利西单抗能在短时间内迅速改善难治性重症RA的各项症状、体征和实验室炎性活动指标,显著改善病情。Objective：To evaluate 8-week effects and adverse reactions of infliximab in patients with severe refractory rheumatoid arthritis（RA）.Methods： Ten patients with severe refractory RA were treated with infliximab（weeks 0,2 and 6）,and clinical,laboratory and psychological indices were recorded 1,4,and 8 weeks after treatment.Results： The clinical,laboratory indices and DAS28 score observed in all of the patients were significantly improved（P0.05）,and no obvious adverse reactions were observed.Conclusion： Infliximab can quickly relieve the symptoms and the activated conditions of severe refractory RA within few weeks.

关 键 词：类风湿关节炎 疗效 英夫利西单抗 

分 类 号：R593.22[医药卫生—内科学] R971.1[医药卫生—临床医学]